Shinichi Takeuchi
Overview
Explore the profile of Shinichi Takeuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakane K, Kawase M, Kato D, Iinuma K, Kawase K, Takeuchi S, et al.
Transl Cancer Res
. 2024 Aug;
13(7):3889-3897.
PMID: 39145084
Background And Objective: Prostate cancer (PCa) is the most common cancer in men. High-risk PCa is associated with an increased risk of PCa-related death. The combined use of androgen deprivation...
2.
Kumada N, Iinuma K, Kubota Y, Takagi K, Nakano M, Ishida T, et al.
Diseases
. 2024 Jun;
12(6).
PMID: 38920554
In this study, we aimed to determine the utility of cytoreductive nephrectomy (CN) in real-world clinical practice and investigate whether CN contributes to improved oncological outcomes in patients with metastatic...
3.
Kumada N, Nakane K, Yamada T, Tomioka-Inagawa R, Sugino F, Namiki S, et al.
Minim Invasive Ther Allied Technol
. 2023 Aug;
32(6):307-313.
PMID: 37607213
This study aimed to investigate the efficacy and safety of robot-assisted radical cystectomy (RARC) in older patients with bladder cancer (BCa). We reviewed the clinical and pathological records of 110...
4.
Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y, et al.
Life (Basel)
. 2023 May;
13(5).
PMID: 37240717
Background: This retrospective single-center cohort study evaluated the efficacy and safety of a combination of neoadjuvant luteinizing hormone-releasing hormone (LHRH) antagonist and tegafur-uracil (UFT) therapy (NCHT) and investigated the medical...
5.
Takeuchi S, Iinuma K, Nakane K, Nakano M, Kawase M, Kawase K, et al.
Curr Oncol
. 2023 Mar;
30(3):2792-2800.
PMID: 36975425
We aimed to determine whether biochemical recurrence-free survival (BRFS) of patients with prostate cancer (PCa) who received low-dose-rate brachytherapy (LDR-BT) differed according to the definition of biochemical recurrence (BCR) after...
6.
Kodana M, Orihara Y, Tezuka M, Takahashi R, Noguchi S, Matsuzaki N, et al.
J Infect Chemother
. 2023 Feb;
29(6):586-591.
PMID: 36849098
Background: In the context of the coronavirus disease 2019 (COVID-19) pandemic, a rapid and reliable point-of-care test is an essential tool for controlling the spread of severe acute respiratory syndrome...
7.
Iinuma K, Yamada T, Kameyama K, Taniguchi T, Kawada K, Ishida T, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765903
We evaluated the efficacy and safety of combination therapy with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKI) as first-line therapy for patients diagnosed as having advanced or metastatic...
8.
Nomura K, Moronuki T, Takeuchi S, Maeda T, Toda K, Kobayashi T
CASE (Phila)
. 2023 Jan;
6(10):462-466.
PMID: 36589342
No abstract available.
9.
Takeuchi S, Iinuma K, Nakano M, Kawase M, Kato D, Kawase K, et al.
Prostate Int
. 2022 Dec;
10(4):224-228.
PMID: 36570651
Background: Iodine-125 low-dose-rate brachytherapy (LDR-BT) is a treatment modality utilized in both localized and advanced prostate cancer (PCa). We aimed to evaluate the long-term oncological outcomes in patients with PCa...
10.
Taniguchi T, Iinuma K, Nakano M, Kawase M, Takeuchi S, Kato D, et al.
Prostate Int
. 2022 Dec;
10(4):207-212.
PMID: 36570644
Background: The aim of this study is to investigate chronological changes of lower urinary tract symptoms (LUTS) in patients with prostate cancer who underwent low-dose-rate brachytherapy (LDR-BT) followed by the...